Cargando…

Angiotensin AT(1) and AT(2) receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia

BACKGROUND/AIMS: The renin-angiotensin system (RAS) is altered in Parkinson’s disease (PD), a disease due to substantia nigra neurodegeneration and whose dopamine-replacement therapy, using the precursor levodopa, leads to dyskinesias as the main side effect. Angiotensin AT(1) and AT(2) receptors, m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivas-Santisteban, Rafael, Rodriguez-Perez, Ana I., Muñoz, Ana, Reyes-Resina, Irene, Labandeira-García, José Luis, Navarro, Gemma, Franco, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430099/ https://www.ncbi.nlm.nih.gov/pubmed/32807174 http://dx.doi.org/10.1186/s12974-020-01908-z

Ejemplares similares

Novel Interactions Involving the Mas Receptor Show Potential of the Renin–Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia
por: Rivas-Santisteban, Rafael, et al.
Publicado: (2021)

Functional Complexes of Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Receptors: Expression in Adult but Not Fetal Lung Tissue
por: Franco, Rafael, et al.
Publicado: (2020)

Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson’s Disease
por: Franco, Rafael, et al.
Publicado: (2020)

Genes Implicated in Familial Parkinson’s Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage
por: Franco, Rafael, et al.
Publicado: (2021)

Adenosine Receptor Antagonists to Combat Cancer and to Boost Anti-Cancer Chemotherapy and Immunotherapy
por: Franco, Rafael, et al.
Publicado: (2021)

The Old and New Visions of Biased Agonism Through the Prism of Adenosine Receptor Signaling and Receptor/Receptor and Receptor/Protein Interactions
por: Franco, Rafael, et al.
Publicado: (2021)

Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs
por: Franco, Rafael, et al.
Publicado: (2023)

Microglial Adenosine Receptors: From Preconditioning to Modulating the M1/M2 Balance in Activated Cells
por: Franco, Rafael, et al.
Publicado: (2021)

Clinical Aspects of Hemilesions of the Cord
Publicado: (1918)

5-Hydroxytryptamine, Glutamate, and ATP: Much More Than Neurotransmitters
por: Franco, Rafael, et al.
Publicado: (2021)

Expression of Melatonin and Dopamine D(3) Receptor Heteromers in Eye Ciliary Body Epithelial Cells and Negative Correlation with Ocular Hypertension
por: Reyes-Resina, Irene, et al.
Publicado: (2020)

Identification of the Ghrelin and Cannabinoid CB(2) Receptor Heteromer Functionality and Marked Upregulation in Striatal Neurons from Offspring of Mice under a High-Fat Diet
por: Lillo, Jaume, et al.
Publicado: (2021)

The NADPH Link between the Renin Angiotensin System and the Antioxidant Mechanisms in Dopaminergic Neurons
por: Franco, Rafael, et al.
Publicado: (2023)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
por: Bispo, Ana Gabrielle, et al.
Publicado: (2023)

Experimental and computational analysis of biased agonism on full-length and a C-terminally truncated adenosine A(2A) receptor
por: Navarro, Gemma, et al.
Publicado: (2020)

Antagonization of OX(1) Receptor Potentiates CB(2) Receptor Function in Microglia from APP(Sw/Ind) Mice Model
por: Raïch, Iu, et al.
Publicado: (2022)

Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
por: König, Eva, et al.
Publicado: (2021)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
por: Herz, Damian M., et al.
Publicado: (2014)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Dopamine in Health and Disease: Much More Than a Neurotransmitter
por: Franco, Rafael, et al.
Publicado: (2021)

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
por: Soares, Nayron Medeiros, et al.
Publicado: (2023)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
por: Teng, Long, et al.
Publicado: (2014)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
por: Guridi, J., et al.
Publicado: (2012)

Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease
por: Herz, Damian M., et al.
Publicado: (2016)

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Pagano, Gennaro, et al.
Publicado: (2017)

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation
por: Li, Michael H., et al.
Publicado: (2018)

Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
por: Gan, Caiting, et al.
Publicado: (2020)

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
por: Chung, Seok Jong, et al.
Publicado: (2020)

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease
por: Song, Tianbin, et al.
Publicado: (2021)

Pallidal Structural Changes Related to Levodopa-induced Dyskinesia in Parkinson's Disease
por: Youn, Jinyoung, et al.
Publicado: (2022)

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
por: Kwon, Destany K., et al.
Publicado: (2022)

Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia
por: Sosero, Yuri L., et al.
Publicado: (2023)

Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia
por: Lopez-Lopez, Andrea, et al.
Publicado: (2023)

Fyn Knock-Down Prevents Levodopa-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease
por: Bordone, Melina P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v8hmi49mj4usrvle67dj5usasf